Management of Lobular Neoplasia

被引：1
作者：
Schnabel F.R. [1 ]
Gooch J.C. [1 ]
Chun J. [1 ]
机构：
[1] NYU Perlmutter Cancer Center, Department of Surgery, New York University Langone Health, 160 East 34th St., New York, 10016, NY
来源：
Current Breast Cancer Reports | 2018年 / 10卷 / 3期
关键词：
ALH; Atypical lobular hyperplasia; LCIS; LN; Lobular carcinoma in situ; Lobular neoplasia;
D O I：
10.1007/s12609-018-0284-9
中图分类号：
学科分类号：
摘要：
Purpose of Review: Lobular neoplasia (LN) is a well-established risk factor and non-obligate precursor for breast cancer. The clinical breast cancer risk assessment and management for these patients can be challenging. Recent Findings: Numerous studies have confirmed that LN is a risk factor and non-obligate precursor for breast cancer. The molecular profile of LCIS is similar to invasive lobular carcinoma. Surgical excision is generally recommended after core biopsy, but there may be a subset of patients with LN who may be observed without surgery. The significant increase in breast cancer risk associated with this disease justifies close surveillance. Chemoprevention is beneficial but uptake remains a challenge. Summary: This paper is a review of the historical and contemporary studies on the clinicopathologic characteristics of LN, the associated risk of breast cancer development, and current management of patients with lobular neoplasia. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码：226 / 231
页数：5
相关论文
共 42 条
  • [1] Khoury T., Karabakhtsian R.G., Mattson D., Yan L., Syriac S., Habib F., Et al., Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases, Histopathology, 64, 7, pp. 981-993, (2014)
  • [2] Clauser P., Marino M.A., Baltzer P.A., Bazzocchi M., Zuiani C., Management of atypical lobular hyperplasia, atypical ductal hyperplasia, and lobular carcinoma in situ, Expert Rev Anticancer Ther, 16, 3, pp. 335-346, (2016)
  • [3] Haagensen C.D., Lane N., Lattes R., Bodian C., Lobular neoplasia (so-called lobular carcinoma in situ) of the breast, Cancer, 42, pp. 737-769, (1978)
  • [4] Foote F.W., Stewart F.W., Lobular carcinoma in situ: a rare form of mammary cancer, Am J Pathol, 17, pp. 491-495, (1941)
  • [5] Giuliano A.E., Connolly J.L., Edge S.B., Mittendorf E.A., Rugo H.S., Solin L.J., Et al., Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 4, pp. 290-303, (2017)
  • [6] Jorns J., Sabel M.S., Pang J.C., Lobular neoplasia: morphology and management, Arch Pathol Lab Med, 138, pp. 1344-1349, (2014)
  • [7] Susnik B., Day D., Abeln E., Bowman T., Krueger J., Swenson K.K., Et al., Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases, Clin Breast Cancer, 16, 6, pp. 507-513, (2016)
  • [8] Calhoun B.C., Collie A.M., Lott-Limbach A.A., Udoji E.N., Sieck L.R., Booth C.N., Et al., Lobular neoplasia diagnosed on breast core biopsy: frequency of carcinoma on excision and implications for management, Ann Diagn Pathol, 25, pp. 20-25, (2016)
  • [9] Portschy P.R., Marmor S., Nzara R., Virnig B.A., Tuttle T.M., Trends in incidence and management of lobular carcinoma in situ: a population-based analysis, Ann Surg Oncol, 20, 10, pp. 3240-3246, (2013)
  • [10] Hartmann L.C., Degnim A.C., Santen R.J., Dupont W.D., Ghosh K., Atypical hyperplasia of the breast—risk assessment and management options, N Engl J Med, 372, 1, pp. 78-89, (2015)
12345